Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
35 Total results for product and free and sample content found
Biomedtracker
19 Oct 2018
Find out what’s in store for the remainder of 2018 with your copy of the Biomedtracker Q4 2018 Outlook Report Extract. This essential analysis of expected Q4 catalysts for 27 drugs is now available to you – for free. Drawn from the full report of the same name, this vital resource explores the likelihood of phase/PDUFA review success and overall Likelihood of Approval (LOA) based on a drug’s phase, drug class, and disease group.
Citeline
By KNect365 28 Aug 2018
Clinical trials are continually evolving, particularly in light of increasing pressures from new technologies and other disruptors. Trends ranging from artificial intelligence (AI) and mHealth to patient-centricity are challenging the industry to innovate against the backdrop of looming regulatory changes and shifting competitor landscapes resulting from M&A activity. In order to explore these trends, KNect365 Life Sciences recently conducted one of the biggest surveys of its kind across clinical trial professionals from within pharma, CROs, sites, service providers, academia and patient groups across the world to look beyond the hype.
Datamonitor Healthcare
27 Aug 2018
Download your complimentary Japan Pharma Outlook 2027 report extract. The 16-page excerpt includes highlights from the full report, which is available to subscribers of Datamonitor Healthcare, and available to purchase on our Report Store. Discover now the complex challenges and opportunities facing Japan Pharma.
Biomedtracker
15 Aug 2018
What's on the horizon for pharma in 2018? Find out with Biomedtracker's Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.
Biomedtracker
15 Aug 2018
Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and regulatory milestones, and Large Impact catalysts for the upcoming quarter.
Meddevicetracker
14 Aug 2018
In this report, we cover catalysts from 10 devices expected to occur in Q3 2018. These include important regulatory milestones and trial data across the cardiovascular, neurology, and endocrine (including diabetes) spaces. Additionally, at the end of this report we have included a list of Large Impact catalysts through Q3 2018.
Pharmaprojects
13 Jul 2018
The discovery and deep investigation of the microbiome has been one of the most significant recent biomedical advances. Extensive research suggests that dysbiosis of the gut microbiome plays a significant role in multiple gastrointestinal (GI) disorders such as; Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).
Pharmaprojects
13 Jul 2018
Welcome to Pharmaprojects’ roundup of key trends in pharmaceutical R&D in 2018, focusing on five key takeaways from our full annual report
Datamonitor Healthcare
By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
Topic Deal trends
No Records Found
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
